Summary Box: FDA meets to review first in trio of obesity drugs seeking approval
By APMonday, July 12, 2010
Summary Box: FDA reviewing 3 new weight loss drugs
WEIGHT LOSS RACE: The Food and Drug Administration this week reviews Vivus’ Qnexa, the first in a trio of new weight loss drugs.
BIG BOTTOMLINE: With U.S. obesity rates nearing 35 percent of adults, expectations are high for the first new prescription drug therapies to emerge in more than a decade. Even a modestly effective drug has blockbuster potential.
NO MAGIC PILL: Experts say none of the three medicines represents a breakthrough in research. Drugmakers have made little headway in understanding and treating the causes of overeating.
Filed under: FDA, Obesity
Tags: Diagnosis And Treatment, Diet And Exercise, Diseases And Conditions, Medication, Nutrition, Weight Management
Tags: Diagnosis And Treatment, Diet And Exercise, Diseases And Conditions, Medication, Nutrition, Weight Management
YOUR VIEW POINT
